Adagene (ADAG) announced the appointment of Dr. Axel Hoos as Executive Advisor. From 2021 to 2024 Dr. Axel Hoos served as CEO of Scorpion Therapeutics
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene’s Promising Position in Next-Gen CTLA-4 Class: Buy Rating Reinforced by Clinical Success and Strategic Optionality
- Adagene’s Strategic Partnerships and Regulatory Milestones Drive Buy Rating
- Adagene price target lowered to $7 from $8 at H.C. Wainwright
- Adagene Announces H1 2025 Financial Results and Strategic Developments
- Adagene initiated with an Outperform at Leerink